Carfilzomib (Kyprolis)

Indications


Pharmacology

  • Proteasome Inhibitor: binds to and irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome (an enzyme which degrades unwanted cellular proteins) -> this inhibition results in accumulation of polyubinquinated proteins, which may cause cell cycle arrest, apoptosis, and inhibition of tumor growth
    • Carfilzomib is Derived from Epoxomicin

Metabolism

  • xxxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • xxxx